Structure Therapeutics (GPCR) Return on Capital Employed (2023 - 2026)
Structure Therapeutics (GPCR) recorded quarterly Return on Capital Employed of 4.2% in Q1 2026, down 62.93% quarter-over-quarter from 2.58% in Q4 2025, and up 168.0% on a YoY basis from 1.57% in Q1 2025.
Structure Therapeutics (GPCR) Return on Capital Employed (2023 - 2026) Analysis & Trends
Structure Therapeutics' Return on Capital Employed history runs 4 years deep, the most recent figure standing at 4.2% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 168.0% year-over-year to 4.2%; the TTM figure through Mar 2026 stood at 4.2% (up 168.0% YoY), while the FY2025 annual figure was 2.5%, up 141.0% from the prior year.
- Return on Capital Employed was 4.2% for Q1 2026 at Structure Therapeutics, down from 2.58% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 2.58% in Q4 2025 to a low of 41.78% in Q3 2023.
- Historically, Return on Capital Employed has averaged 18.69% across 4 years, with a median of 15.68% in 2024.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed soared 2877 bps in 2024, then jumped 33 bps in 2025.
- A 4-year view of Return on Capital Employed shows it stood at 31.68% in 2023, then jumped by 91 bps to 2.91% in 2024, then grew by 11 bps to 2.58% in 2025, then slumped by 63 bps to 4.2% in 2026.
- The last three Return on Capital Employed figures came in at 4.2% (Q1 2026), 2.58% (Q4 2025), and 15.0% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -107.40% |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -50.43% |
| 10 | Structure Therapeutics | 9.35 Bn | 9.35 Bn | - | -4.20% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.20% |
| Dec 31, 2025 | -2.58% |
| Sep 30, 2025 | -15.00% |
| Jun 30, 2025 | -10.85% |
| Mar 31, 2025 | -5.89% |
| Dec 31, 2024 | -2.91% |
| Sep 30, 2024 | -15.68% |
| Jun 30, 2024 | -18.02% |
| Mar 31, 2024 | -25.81% |
| Dec 31, 2023 | -31.68% |
| Sep 30, 2023 | -41.78% |
| Jun 30, 2023 | -31.91% |
| Mar 31, 2023 | -36.67% |